Latest news articles

Added 1 month ago Drug news

FDA approves Xembify, a 20% subcutaneous immunoglobulin to treat primary immunodeficiencies

Grifols announced that Xembify, its new 20% subcutaneous immunoglobulin, has been approved by the FDA. Xembify is used to treat...

Added 3 months ago Drug news

Phase III APeX-2 trial of BCX 7353 reported data for treatment of hereditary angioedema

BioCryst Pharmaceuticals, Inc. announced that the randomized (n=121), double-blind, placebo-controlled, Phase III APeX-2 trial of once-daily, oral BCX 7353 for...

Added 4 months ago Drug news

FDA approves Asceniv to treat primary humoral immunodeficiency disease

ADMA Biologics, Inc. announces that the FDA has approved Asceniv Immune Globulin Intravenous, Human – slra 10% Liquid, formerly referred...

Search all news articles for Immunity disorders
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

EADV 2018 Highlights

EADV 2018 Highlights

EADV Congress 2018: Bringing you the latest news and insights from 27th EADV Congress, 12-16 September 2018 Paris, France.

Oral Anticoagulation Reversal

Oral Anticoagulation Reversal

Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients.

Load more

Guidelines

ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients

This part of the European Fungal Infection Study Group (EFISG) of the European Society of Clinical Microbiology and Infectious Diseases...

Added 6 years ago

Search all guidelines for Immunity disorders
 

Journal articles

Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies.

In patients with primary antibody deficiencies, subcutaneous administration of IgG (SCIG) replacement is effective, safe, well-tolerated, and can be self-administered at home. A new SCIG replacement at 20% concentration (Hizentra®)...

Added 1 year ago

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection.

Rituximab, a monoclonal antibody that targets CD20 on B cells, is now central to the treatment of a variety of malignant and autoimmune disorders.

Added 2 years ago

Human immunoglobulin 10 % with recombinant human hyaluronidase: replacement therapy in patients with primary immunodeficiency disorders

Human immunoglobulin is an established replacement therapy for patients with primary immunodeficiency disorders (PIDs). Recombinant human hyaluronidase (rHuPH20) is a...

Added 5 years ago

Search all journal articles for Immunity disorders
 
Lauren McCracken

Lauren McCracken works for our sister agency Digital Medical Communications (DMC Ltd) as an Associate Medical Writer. Lauren is very passionate about healthcare and how technology can improve treatments, and has written a blog series 'Transforming lives through technology'

... Read more

EAACI hot topics: Allergen specific immunotherapy (AIT)

When should AIT be used to treat your patients with allergies? Is it right for every allergy? And do we really know the long-term effects of this treatment? This blog highlights some of the talking points surrounding AIT discussed at this year’s EAACI Congress.